Tuberculosis cost-effectiveness of therapy: Difference between revisions

Jump to navigation Jump to search
 
(11 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Tuberculosis}}
{{Tuberculosis}}
{{CMG}} ; {{AE}} {{Ammu}}
{{CMG}} ; {{AE}} {{Mashal Awais}}; {{Ammu}}
==Overview==
==Overview==
Treatment of tuberculosis must be analysed for relative cost effectiveness of inpatient and outpatient models of care as it will benefit regions where tuberculosis is highly prevalent. Unless there is severe complications it is highly recommended to treat the TB patient in ambulatory care rather than inpatient services.
[[Tuberculosis]] [[treatment]] must be evaluated for relative cost-effectiveness of [[inpatient]] and [[outpatient]] models of [[Care centers|care]] as it will benefit regions where [[tuberculosis]] is [[Endemic (epidemiology)|endemic]]. It is highly recommended to treat the [[Tuberculosis|TB]] patient in [[ambulatory care]] instead of [[inpatient]] setting unless there are severe [[Complication (medicine)|complications]].<ref name="pmid22070215">{{cite journal| author=Fitzpatrick C, Floyd K| title=A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. | journal=Pharmacoeconomics | year= 2012 | volume= 30 | issue= 1 | pages= 63-80 | pmid=22070215 | doi=10.2165/11595340-000000000-00000 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22070215  }} </ref>


==Cost effectiveness of therapy==
==Cost effectiveness of therapy==
While measurements of morbidity and mortality are key considerations for estimating the burden of disease in populations, they provide an incomplete picture of the adverse impact of ill health on human welfare. In particular, the economic consequences of poor health can be substantial.
While measurements of morbidity and mortality are important considerations for estimating the burden of disease in populations, they give an incomplete picture of the adverse effect of sickness on human welfare especially the economic consequences of poor health that may be substantial.


Analysis of the economic impact of ill-health addresses a number of policy questions concerning the consequences of disease or injury. Some of these questions relate to the microeconomic level of households, firms or government – such as the impact of ill-health on a household’s income or a firm’s profits – while others relate to the macroeconomic level, including the aggregate impact of a disease on a country’s current and future gross domestic product (GDP).
Analysis of the economic effect of the disease addresses multiple policy questions regarding the results of disease. Some of these questions are associated with the microeconomic level of households, firms, or government – such as the effect of the disease on a household’s income or a firm’s profits – while others relate to the macroeconomic level, including the cumulative effect of a disease on a country’s currency and future gross domestic product (GDP).


WHO proposes a defined conceptual framework within which the economic impact of diseases and injuries can be considered and appropriately estimated. <ref name=WHO>{{cite web | title = Cost effectiveness and strategic planning| url = http://www.who.int/choice/economicburden/en/ }}</ref>
[[World Health Organization|WHO]] suggests a outlined conceptual framework within which the economic burden of diseases and injuries can be appropriately estimated. <ref name="WHO">{{cite web | title = Cost-effectiveness and strategic planning| url = http://www.who.int/choice/economicburden/en/ }}</ref>


The cost effectiveness in various tubercular control interventions in Africa region is give below. <ref name=Cost>{{cite web | title = Cost effectiveness with TB control interventions| url = http://www.who.int/choice/publications/p_2005_MDG_series_TB.pdf?ua=1}}</ref>
The cost of the current regimen is approximately 4000 US$ per patient excluding laboratory, human resource, and patient opportunity costs. <ref name="Cost">{{cite web | title = Cost effectiveness purposed by WHO| url = http://www.who.int/bulletin/volumes/92/1/13-122028/en/}}</ref>


{| style="border: 0px; font-size: 90%; margin: 3px; width: 500px;" align=center
 
|valign=top|
The cost-effectiveness in various tubercular control interventions in Africa region is given below. <ref name="Cost">{{cite web | title = Cost effectiveness with TB control interventions| url = http://www.who.int/choice/publications/p_2005_MDG_series_TB.pdf?ua=1}}</ref>
 
{| style="border: 0px; font-size: 90%; margin: 3px; width: 500px;" align="center"
| valign="top" |
|+
|+
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Intervention}}
! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Intervention}}
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Yearly costs with 95% coverage level}}
! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Yearly costs with 95% coverage level}}
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Minimal DOTS
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Minimal DOTS
| style="padding: 5px 5px; background: #F5F5F5;" | 366.3 million $
| style="padding: 5px 5px; background: #F5F5F5;" |366.3 million $
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Full DOTS
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Full DOTS
Line 35: Line 38:
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
{{WH}}
{{WS}}


[[Category:Disease]]
[[Category:Disease]]
[[Category:Infectious disease]]
[[Category: Pulmonology]]
[[Category:Pulmonology]]
[[Category:Primary care]]
[[Category:Bacterial diseases]]
[[Category:Bacterial diseases]]
{{WH}}
{{WS}}

Latest revision as of 05:22, 27 March 2021

Tuberculosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Tuberculosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Children

HIV Coinfection

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Special Conditions
Drug-resistant

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Tuberculosis cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Tuberculosis cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Tuberculosis cost-effectiveness of therapy

CDC on Tuberculosis cost-effectiveness of therapy

Tuberculosis cost-effectiveness of therapy in the news

Blogs on Tuberculosis cost-effectiveness of therapy

Directions to Hospitals Treating Tuberculosis

Risk calculators and risk factors for Tuberculosis cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Mashal Awais, M.D.[2]; Ammu Susheela, M.D. [3]

Overview

Tuberculosis treatment must be evaluated for relative cost-effectiveness of inpatient and outpatient models of care as it will benefit regions where tuberculosis is endemic. It is highly recommended to treat the TB patient in ambulatory care instead of inpatient setting unless there are severe complications.[1]

Cost effectiveness of therapy

While measurements of morbidity and mortality are important considerations for estimating the burden of disease in populations, they give an incomplete picture of the adverse effect of sickness on human welfare especially the economic consequences of poor health that may be substantial.

Analysis of the economic effect of the disease addresses multiple policy questions regarding the results of disease. Some of these questions are associated with the microeconomic level of households, firms, or government – such as the effect of the disease on a household’s income or a firm’s profits – while others relate to the macroeconomic level, including the cumulative effect of a disease on a country’s currency and future gross domestic product (GDP).

WHO suggests a outlined conceptual framework within which the economic burden of diseases and injuries can be appropriately estimated. [2]

The cost of the current regimen is approximately 4000 US$ per patient excluding laboratory, human resource, and patient opportunity costs. [3]


The cost-effectiveness in various tubercular control interventions in Africa region is given below. [3]

Intervention Yearly costs with 95% coverage level
Minimal DOTS 366.3 million $
Full DOTS 612.2 million $
Minimal DOTS with resistant cases 495.9 million $
Full combination 739.4 million $

References

  1. Fitzpatrick C, Floyd K (2012). "A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis". Pharmacoeconomics. 30 (1): 63–80. doi:10.2165/11595340-000000000-00000. PMID 22070215.
  2. "Cost-effectiveness and strategic planning".
  3. 3.0 3.1 "Cost effectiveness purposed by WHO".

Template:WH Template:WS